Houston-based Moleculin Biotech (Nasdaq: MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, informed the world that they filed a patent application for their investigational product, WP1122, and its analogs and therapies to limit the ability of coronavirus and other viruses to replicate. The patent covers joint discoveries which manifest during an ongoing research agreement. This coincided with the biotech entering into an agreement with the University of Texas Medical Branch at Galveston (UTMB) to test WP1122 against a range of viruses including COVID-19.
The Deal with University of Texas Medical Branch at Galveston (UTMB)
On March 16, UTMB and Moleculin Biotech announced a deal to conduct research on the company’s patented portfolio of molecular inhibitors, including WP1122 for antiviral properties against a range of viruses, including COVID-19. A hub of research, UTMB partners with other academic partners, private foundations, and the biopharma industry.
Government Money and Agencies Involved
As it turns out, UTMB’s Center for Biodefense and Emerging Infectious Diseases has ongoing agre...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).